We appreciate the review of our article1 by Dr Condliffe and colleagues. We agree that unadjusted outcomes of incident and prevalent populations of patients with pulmonary arterial hypertension (PAH) differ.2 Therefore, it is paramount that target populations are explicitly described when reporting data obtained from large registries. REVEAL (the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) was designed to observe and characterize a patient population encountered in daily clinical practice; thus, consecutive patients from 55 US PAH Centers were enrolled. These included (1) patients with established disease who previously underwent right-sided heart catheterization (RHC) and were receiving PAH-specific therapies at the time of enrollment, and (2) newly diagnosed patients who had recently undergone diagnostic RHC. In our report, we estimated 1-year survival from the date of enrollment for established and newly diagnosed patients with connective tissue disease associated-PAH (CTD-APAH).1 Survival differed by type of CTD: patients with systemic sclerosis (SSc) had the poorest survival (82%), followed by those with systemic lupus erythematosus (94%), mixed connective tissue disease (88%), and rheumatoid arthritis (96%).1 Although these estimates are valid and generalizable to patients with CTD-APAH seen in clinical practice, we agree that they are not generalizable to the much smaller clinical population of patients with CTD with exclusively incident PAH.